Oxford Cannabinoid Technologies Holdings Plc (OCTHF) es una empresa que cotiza en bolsa en el Salud sector, operando dentro de la Biotecnología industria. La empresa tiene su sede en London, United Kingdom. El CEO actual es Clarissa Ann Sowemimo-Coker.
OCTHF tiene fecha de IPO 2021-10-20, 5 empleados a tiempo completo, cotiza en el Other OTC, una capitalización de mercado de $3.05M.
Oxford Cannabinoid Technologies Holdings Plc, a pharmaceutical company, engages in the research, development, and commercialization of cannabinoid-based prescription medicines. Its lead drug candidate is OCT461201, a selective CB2 receptor agonist in solid oral dosage form that is in pre-clinical development for use in the treatment of IBS-associated visceral pain, as well as neuropathic pain conditions, including post herpetic neuralgia. The company is also developing OCT130401, which is in pre-clinical development for the treatment of trigeminal neuralgia. Oxford Cannabinoid Technologies Holdings Plc was incorporated in 2017 and is headquartered in London, the United Kingdom.
